Camp4 Therapeutics CORP Form 4 insider transactions

5AM Partners VI, LLC and 6 others reported changes in beneficial ownership of Camp4 Therapeutics Corp common stock on August 3, 2026.

Andrew J. Schwab, a Director of Camp4 Therapeutics Corp, received 3,179,558 shares of common stock on August 3, 2026.

Richard A Young, a Director of Camp4 Therapeutics Corp, purchased 16,378 shares of common stock on August 3, 2026 for $1.65 per share.

Yuri Maricich, Chief Medical Officer of Camp4 Therapeutics Corp, purchased 6,551 shares of common stock on August 3, 2026 for $1.65 per share.

Kelly Gold, Chief Financial Officer of Camp4 Therapeutics Corp, purchased 6,551 shares of common stock on August 3, 2026 for $1.65 per share.

Josh Mandel-Brehm, Chief Executive Officer and a Director of Camp4 Therapeutics Corp, purchased 6,551 shares of common stock on August 3, 2026 for $1.65 per share.

Director Douglas E. Williams was granted 28,000 stock options in Camp4 Therapeutics Corp.

Camp4 Therapeutics Director Steven H Holtzman acquired 28,000 stock options with an exercise price of $4.34, vesting on the earlier of one year or the next annual meeting.

Camp4 Therapeutics Director Stewart Murray acquired 28,000 stock options at $4.34 per share, vesting over one year.

Camp4 Therapeutics Director and 10% owner Amir Nashat acquired 28,000 stock options with an exercise price of $4.34.

Daniel Tardiff, Chief Scientific Officer at Camp4 Therapeutics Corp, was granted a stock option for 170,000 shares.

Yuri Maricich, Chief Medical Officer of Camp4 Therapeutics Corp, was granted stock options for 215,000 shares.

Camp4 Therapeutics Corp. reports that Chief Financial Officer Kelly Gold acquired 215,000 stock options with an exercise price of $4.46.

Camp4 Therapeutics Corp. reports that CEO Josh Mandel-Brehm acquired 580,000 stock options with an exercise price of $4.46.

Director Michael MacLean acquired 56,000 stock options in Camp4 Therapeutics Corp. on April 1, 2026, as detailed in a Form 4 filing.

Camp4 Therapeutics' Chief Scientific Officer, Daniel Tardiff, acquired 145,500 stock options with an exercise price of $6.01, vesting over three years.

Camp4 Therapeutics' Chief Medical Officer, Yuri Maricich, was granted 190,000 stock options with an exercise price of $6.01, vesting over three years.

Camp4 Therapeutics CFO Kelly Gold was granted 190,000 stock options with an exercise price of $6.01, vesting over three years.

Camp4 Therapeutics CEO Josh Mandel-Brehm was granted 425,000 stock options with an exercise price of $6.01, vesting over three years.

Andrew J. Schwab, a Director and 10% owner of Camp4 Therapeutics Corp, acquired 2,941,176 shares of common stock at $1.53 per share through a pre-arranged 10b5-1 plan.

5AM Partners VI, a significant shareholder and director, acquired over 2.9 million shares of Camp4 Therapeutics common stock at $1.53 per share.

Polaris Management Co. VII and related entities acquired over 1.3 million shares of Camp4 Therapeutics common stock in a private placement.

A director and 10% owner of Camp4 Therapeutics Corp, Amir Nashat, is scheduled to acquire common stock through affiliated entities in a private placement on September 11, 2025.

Camp4 Therapeutics' Chief Medical Officer, Yuri Maricich, acquired 6,060 shares of common stock at $1.65 per share in a private placement.

Camp4 Therapeutics CFO Kelly Gold acquired 6,060 shares of common stock at $1.65 per share in a private placement.

Camp4 Therapeutics CEO Josh Mandel-Brehm acquired 6,060 shares of common stock at $1.65 per share in a private placement.

Camp4 Therapeutics Director Richard A. Young acquired 15,151 shares of common stock at $1.65 per share in a private placement.

James P. Boylan, a Director at Camp4 Therapeutics Corp, was granted 9,000 stock options with an exercise price of $1.56, vesting over one year or by the next annual meeting.

Camp4 Therapeutics Corp. Director Richard A. Young reported the acquisition of 9,000 stock options with an exercise price of $1.56, vesting on the earlier of the first anniversary of the grant date or the next annual meeting.

Camp4 Therapeutics Corp. director Michael J Higgins was granted 9,000 stock options with an exercise price of $1.56, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.